The Centers For Medicare & Medicaid Services Issued A Permanent & Product-specific J-code For BioXcel Therapeutics' Igalmi Sublingual Film, Approved For The Acute Treatment Of Agitation Associated With Schizophrenia Or Bipolar I Or II Disorder In Adults
Portfolio Pulse from Benzinga Newsdesk
The Centers for Medicare & Medicaid Services has issued a permanent and product-specific J-code for BioXcel Therapeutics' Igalmi Sublingual Film, which is approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The IGALMI J-Code J1105 will become effective from January 1, 2024.
October 30, 2023 | 11:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioXcel Therapeutics' Igalmi Sublingual Film has received a permanent J-code from the Centers for Medicare & Medicaid Services, which will become effective from January 1, 2024. This could potentially increase the product's accessibility and usage.
The issuance of a permanent J-code for BioXcel Therapeutics' Igalmi Sublingual Film by the Centers for Medicare & Medicaid Services is a positive development for the company. This code is used for billing purposes and could potentially increase the product's accessibility and usage, which could in turn boost the company's revenues. Therefore, this news is likely to have a positive impact on BioXcel Therapeutics' stock in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100